Dana-Farber Cancer Institute | Strategic Alliance Partners

September 12, 2023

Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.

September 11, 2023

Osimertinib in combination with platinum-based therapy and pemetrexed demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer.

September 11, 2023

Details of steroid use for chronic GVHD, including taper and response criteria, are described by the panel.

September 11, 2023

The panel provides an overview of the frontline treatments available for chronic GVHD.

September 11, 2023

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

August 29, 2023

Sara M. Tolaney, MD, MPH, highlights updated survival and safety data seen with sacituzumab govitecan in patients with hormone receptor–positive, HER2-negative breast cancer; underscores how Trop-2 and HER2 testing is not necessarily needed for this agent in this population at this time; and shares how ongoing efforts are exploring the utilization of this agent earlier in the treatment course.

August 24, 2023

Interim data from the phase 3 CABINET trial demonstrated significant improvement in progression-free survival with cabozantinib vs placebo in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors following progression on prior systemic therapy.

August 24, 2023

Pasi A. Jänne, MD, PhD, discusses the advantages of bispecific ADCs that target both HER3 and EGFR; preliminary efficacy and safety data seen with BL-B01D1 in patients with non–small cell lung cancer; and the activity of this agent in patients with head and neck squamous cell carcinoma, small cell lung cancer, and nasopharynx cancer.

August 22, 2023

Paolo Tarantino, MD, discusses the use of antibody drug conjugates in patients with hormone receptor-positive breast cancer.

August 21, 2023

Marios Giannakis, MD, PhD, discusses how targeting the WNT signaling pathway could harness a previously underutilized pathway involved in GI tumor development, spotlights the activity and safety of CGX1321 with or without pembrolizumab in phase 1 studies, and emphasizes the need for continued investigation of CGX1321 to further validate this precision medicine approach.

August 21, 2023

Drs Gootpu and Inyang explain use of corticosteroids as frontline treatment for acute GHVD.

August 21, 2023

Dr Gooptu shares guidance on the assessment and grading of acute GVHD.

August 18, 2023

Praful K. Ravi, MB, BChir, MRCP, discusses the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer, highlighting the use of the targeted radioligand lutetium Lu 177 vipivotide tetraxetan.

August 18, 2023

Paolo Tarantino, MD, discusses typical conversations oncologists should have with patients regarding the platinum chemotherapy shortage, as well as the importance of honest communication about treatment regimen changes.

August 15, 2023

Recent years have brought tremendous progress in demonstrating that there is hope for improving mortality from pancreatic ductal adenocarcinoma through early detection.

August 14, 2023

Acute GVHD presentation and diagnosis is assessed for the clinical scenario previously discussed.

August 14, 2023

GVHD prophylaxis techniques are analyzed by the panelists.

August 14, 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

August 10, 2023

The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.

August 10, 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.